- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03919656
SGLT-2 Inhibition, Metabolomics and Cardiovascular/Kidney Disease
SGLT-2 Inhibition and Cardiovascular Disease. Metabolomics Study of Potential Factors Involved in Cardio- and Nephroprotection
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this study, we hypothesize that metabolomics changes that occur in patients with T2DM after initiating SGLT2i (sodium-glucose cotransporter 2 inhibitors) treatment may be responsible for the beneficial cardiovascular and kidney effects observed in clinical trials with SGLT2i. Also, we propose that the study of the specific metabolome associated with the treatment with SGLT2i could help identify the possible metabolites and molecules that reduce CVD (cardiovascular disease) and renal disease in patients with T2DM.
The participants in the study will be randomized to receive 10 mg dapagliflozin or placebo once daily of for 12 weeks. Besides, all participants will be advised to engage in 150 min or more of moderate-to vigorous intensity physical activity per week, spread over at least 3 days/week, with no more than 2 consecutive days without activity and to engage in 2-3 sessions/week of resistance exercise on nonconsecutive days. Moreover, these patients will be advised to follow a lifestyle program that achieve a 500-750 kcal/day energy deficit or provide≈1,200-1,500 kcal/day for women and 1,500-1,800 kcal/day for men, adjusted for the individual's baseline body weight.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Jose Carlos Fernandez-Garcia, MD, PhD
- Phone Number: +34951034016
- Email: josecarlosfdezgarcia@hotmail.com
Study Locations
-
-
-
Malaga, Spain, 29010
- Virgen de la Victoria University Hospital. Endocrinology Department
-
Contact:
- Jose Carlos Fernández García, MD, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18-75.
- BMI 27-39.9 kg/m2.
- T2DM on treatment with metformin and inadequate metabolic control (defined as HbA1c≥6.5 -7%).
Exclusion Criteria:
- Pregnancy (all women of child-bearing age, unless on treatment with contraceptive methods, will undergo a pregnancy test)
- Breastfeeding
- Intolerance/allergy to dapagliflozin.
- Treatment with antidiabetic drug other than metformin.
- Impaired kidney function: Estimated glomerular filtration rate (eGFR) <60 ml/min/1.73m2 (calculated using the CKD-EPI formula).
- Patients with established cardiovascular disease.
- Previous or current history of cancer of any kind.
- Uncontrolled hypertension (systolic blood pressure≥160 mmHg or diastolic blood pressure≥110 mmHg, despite adequate antihypertensive treatment).
- History of liver tumour or acute or chronic liver disease with impaired liver function: total bilirubin levels> 2.0 mg / dl or GOT/GPT levels three times higher than normal upper limit.
- Known HIV infection or active HBV or HCV infection.
- Other serious underlying diseases, which could affect the patient's ability to participate in the study.
- Reduced life expectancy (<12 months) due to advanced or terminal concomitant diseases.
In addition, female patients of child-bearing age will be advised to use contraceptive methods during the study period, given the contraindication of dapagliflozin and metformin during pregnancy as per normal clinical practice.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dapagliflozin
Dapagliflozin 10 mg daily (orally)
|
Dapagliflozin 10 mg daily in a green, plain, diamond shaped, film coated tablet (orally)
Other Names:
|
Placebo Comparator: Placebo
Matching placebo for dapagliflozin daily (orally).
Does not contain active ingredient
|
Green, plain, diamond shaped, film coated tablet (orally).
Does not contain active ingredient
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Metabolomics changes in blood
Time Frame: From baseline to week 12
|
Targeted and quantitative analysis by ultra-high-resolution liquid chromatography coupled to triple quadrupole mass spectrometry (UHPL-QqQ/MS).
Analysis of specific families of metabolites selected from hypotheses generated by previous exploratory studies: changes in acylcarnitines and other intermediates of mitochondrial β-oxidation and the urea cycle, branched-chain amino acids and biogenic amines
|
From baseline to week 12
|
Metabolomics changes in urine
Time Frame: From baseline to week 12
|
Targeted and quantitative analysis by ultra-high-resolution liquid chromatography coupled to triple quadrupole mass spectrometry (UHPL-QqQ/MS).
Analysis of specific families of metabolites selected from hypotheses generated by previous exploratory studies: changes in acylcarnitines and other intermediates of mitochondrial β-oxidation and the urea cycle, branched-chain amino acids and biogenic amines
|
From baseline to week 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
BMI (body mass index) changes
Time Frame: From baseline to to week 12
|
Measured by body composition analysis
|
From baseline to to week 12
|
Changes in insulin resistance
Time Frame: From baseline to to week 12
|
Measured as HOMA-IR (homeostatic model assessment of insulin resistance)
|
From baseline to to week 12
|
Changes in metabolic control
Time Frame: From baseline to to week 12
|
Measured as HbA1c (glycated hemoglobin)
|
From baseline to to week 12
|
Changes in Quality of Life: 36-Item Short Form Health Survey (SF-36) questionnaire
Time Frame: From baseline to to week 12
|
The SF-36 has eight scaled scores: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health.
The scores are weighted sums of the questions in each section.
Scores range from 0 - 100, lower scores indicate more disability, and higher scores indicate less disability
|
From baseline to to week 12
|
Changes in albuminuria
Time Frame: From baseline to to week 12
|
Modifications in albuminuria, measured as albumin excretion rate (AER)
|
From baseline to to week 12
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jose Carlos Fernandez-Garcia, MD, PhD, Virgen de la Victoria Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- FIM-DAPA-2018-01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
University Hospital Inselspital, BerneCompletedType 2 Diabetes MellitusSwitzerland
-
India Diabetes Research Foundation & Dr. A. Ramachandran...CompletedTYpe 2 Diabetes MellitusIndia
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
AstraZenecaRecruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on Dapagliflozin 10 mg
-
AstraZenecaNot yet recruitingChronic Kidney DiseaseUnited States, Austria, Italy, Spain, Canada, Malaysia, Taiwan, Poland, Bulgaria
-
AstraZenecaNot yet recruitingHeart Failure and Impaired Kidney FunctionUnited States, Canada, Finland, France, Germany, Italy, Spain, United Kingdom, Thailand, Vietnam, Korea, Republic of, Mexico, Peru, Philippines, Turkey, China, Taiwan, Austria, Slovakia, Chile, Argentina, Japan, Czechia, Greece, Hungary, ... and more
-
Damanhour UniversityRecruitingHeart Failure | Reduced Ejection Fraction Heart FailureEgypt
-
AstraZenecaCompleted
-
Abramson Cancer Center of the University of PennsylvaniaTerminatedAcute Myeloid LeukemiaUnited States
-
Medical University of ViennaVienna Dialysis CenterRecruitingDiabetes Mellitus, Type 2 | Hemodialysis | Chronic Kidney Disease | Kidney Failure | Left Ventricular HypertrophyAustria
-
AstraZenecaCompletedBioequivalence | Fixed Dose Combination Tablets | Healthy Male and Female SubjectsUnited States
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Completed
-
Jiangsu Hansoh Pharmaceutical Co., Ltd.Completed
-
AstraZenecaTerminatedType 2 Diabetes MellitusThailand, Vietnam